Quick Facts

• Primary Application: Used to assist in the conversion of a rapid, irregular heart rhythm (paroxysmal supraventricular tachycardia, or PSVT) to a normal rhythm.
• Diagnostic Use: Employed in cardiac stress testing to assist in the evaluation of heart function.

---

What Adenosine Treats: Main Uses and Benefits

Adenosine is a medicinal agent with established applications in cardiology. The primary therapeutic use of this medication is to facilitate the conversion of paroxysmal supraventricular tachycardia (PSVT) back to a regular heart rhythm (sinus rhythm). PSVT is a type of arrhythmia characterized by episodes of abnormally fast heartbeats arising from above the ventricles.

The medication is administered in a controlled clinical setting to address these rapid heart episodes, including those associated with specific accessory bypass tracts, such as in Wolff-Parkinson-White Syndrome.

In addition to its role in managing certain arrhythmias, Adenosine also serves a diagnostic purpose. It is utilized as an adjunct to thallium-201 myocardial perfusion scintigraphy in individuals who are unable to complete adequate exercise testing. This application assists medical professionals in evaluating blood flow to the heart muscle.

Who Can and Cannot Use Adenosine? — Official Regulatory Information

The use of adenosine is strictly governed by regulatory documentation, which defines specific populations who must not receive the medicine (contraindications) and others for whom use requires special consideration.

Contraindicated Populations (Must Not Use):

• Individuals with second- or third-degree atrioventricular (A-V) block or Sinus Node Disease (such as sick sinus syndrome or symptomatic bradycardia), unless a functioning artificial pacemaker is in place.
• Individuals with bronchoconstrictive or bronchospastic lung disease (e.g., asthma).
• Individuals with a known hypersensitivity or allergy to adenosine.
• Individuals with Long QT syndrome (as specified in some regulatory documents).

Populations Requiring Special Consideration:

• Pediatric patients (under 18): Safety and effectiveness have not been established.
• Pregnancy and Lactation: Use is generally not recommended unless the physician determines the potential benefit outweighs the unknown risk.
• Cardiovascular Conditions: Use requires caution in patients with first-degree A-V block, bundle branch block, or symptoms of acute myocardial ischemia.

Officially documented interaction patterns for Adenosine are primarily structured around two classes of substances: those that significantly increase its effects and those that reduce its efficacy. The interaction profile is defined by specific restrictions and mandatory timing rules from regulatory bodies.

Interactions Increasing Effect (Potentiation)

Co-administration with Nucleoside Transport Inhibitors, specifically the medicine Dipyridamole, is severely restricted, often classified as a contraindication in regulatory labeling. Dipyridamole prevents the cellular clearance of Adenosine, resulting in a documented increase in its concentration and cardiovascular effects. Due to this official restriction, Dipyridamole must generally be discontinued 12 to 24 hours prior to Adenosine administration.

Interactions Reducing Effect (Antagonism)

The efficacy of Adenosine can be reduced or abolished by the presence of Methylxanthines, a class that includes the medicine Theophylline and the substance Caffeine found in common foods and beverages. This is a documented interaction based on competitive receptor antagonism. Regulatory guidelines advise that products containing Caffeine should be withheld for several hours prior to Adenosine use.

Conduction-Related Additive Effects

Other medicines that depress heart conduction, such as Carbamazepine and other nodal-blocking agents, are officially noted to carry a risk of additive pharmacodynamic effects, which may increase the likelihood of developing atrioventricular (AV) block.

How Adenosine Works: Mechanism of Action

---

Cardiac Electrical Signal Dampening

Adenosine acts as a full agonist on all four adenosine receptor subtypes, primarily targeting A1 receptors concentrated in the atrioventricular (AV) node. A1 activation initiates an inhibitory cascade via Gi proteins, which leads to the opening of potassium channels and inhibition of calcium channels. This ion flux results in cell hyperpolarization and suppression of electrical activity, producing a profound, transient slowing or blocking of the electrical impulse through the AV node.

---

Vascular Tone and Blood Flow Modulation

Simultaneously, the molecule activates A2A receptors on vascular smooth muscle. This engages a stimulatory cascade (via Gs protein) that rapidly increases intracellular cAMP. The resulting molecular change induces the smooth muscle in the vessel walls to relax, leading to immediate widespread vasodilation and a transient alteration of systemic blood pressure and local blood flow dynamics.

---

⏳ Mechanism Constraints and Rapid Clearance

As an endogenous nucleoside, the biological effects are constrained by extremely rapid metabolism (via adenosine deaminase) and cellular reuptake. This rapid clearance determines that the resulting physiological changes—including cardiac slowing ( A1) and vascular widening ( A2A) effects—are transient, typically resolving within seconds.

Adenosine is administered strictly by the intravenous (IV) route and is not available for oral or long-term use. Due to its ultra-short duration of action, its administration requires a highly specific procedural protocol carried out only in a hospital or specialized setting with continuous cardiac monitoring and resuscitation equipment immediately available.

Administration for Acute Episodes

The most common use, addressing acute supraventricular tachycardia, follows a rapid, escalating bolus regimen. The recommended initial adult dose is 6 mg administered as a rapid IV push (over 1–3 seconds), followed immediately by a 20 mL saline flush to ensure rapid delivery to the central circulation. If the initial dose does not achieve the intended result within 1 to 2 minutes, a second dose of 12 mg may be administered. A third 12 mg dose may follow if necessary. For adults, the maximum single dose is 12 mg.

Administration for Diagnostic Procedures

For use during a pharmacological cardiac stress test, Adenosine is administered differently, using a continuous peripheral IV infusion at a rate of 0.14 mg/kg/min over a fixed period of six minutes. The required diagnostic tracer is injected at the midpoint of the infusion (after the first three minutes).

Dosage Adjustments

Specific official instructions exist for dose modification in certain contexts. For instance, the initial adult dose should be reduced to 3 mg when administered through a central venous line or in patients receiving certain potentiating agents, such as dipyridamole. Pediatric dosing for acute episodes is also adjusted based on the patient's weight, starting with a smaller initial bolus and escalating as needed.

Research Evidence / Overview of Studies for Adenosine

Evidence for use in Paroxysmal Supraventricular Tachycardia (PSVT)

Studies have explored the use of Adenosine for use in conditions characterized by fluctuating or episodic manifestations, specifically focusing on Paroxysmal Supraventricular Tachycardia (PSVT). The majority of the evidence comes from relevant trials assessing short-term or episodic symptom patterns, often conducted in clinical settings during research exploring short-term symptom changes. Studies monitored measurements related to the heart's electrical system, with studies monitoring outcomes describing episodic or acute changes in heart rhythm.

Findings describe patterns observed in the studies related to the temporary patterns observed in the heart rhythm measurements associated with PSVT. While these studies provide insight into short-term changes, evidence is limited regarding the consistency of the observed short-term patterns. Follow-up durations were limited in most of the existing research.

Evidence for use in Myocardial Perfusion Imaging (MPI)

Adenosine was studied for its application in Myocardial Perfusion Imaging (MPI), which involves assessing blood flow to the heart muscle. Research examined how the compound is used in combination with cardiac imaging techniques. It was evaluated for its role in enabling temporary physiological strain for imaging purposes. The measured outcomes included outcomes monitoring physiological strain or stress as captured by the imaging scans themselves, which are relevant in evidence describing how physiological changes are measured during the procedure.

Data show patterns related to temporary changes in blood flow within the heart muscle. Research for this use is primarily based on settings evaluating diagnostic procedures over defined time intervals. Consequently, there is limited information for long-term outcomes associated with repeated use.

What is still uncertain about Adenosine

Evidence quality varies across studies, and findings were mixed in some areas. Long-term effects are not fully established. Data for certain special populations, such as children or those with specific unique comorbid conditions, remain insufficient. The research provides context but not individual predictions; it primarily describes group patterns observed during specific research scenarios. Research is ongoing to better characterize the full scope of outcomes.

Common questions about Adenosine (FAQ)

---

Q: What is the specific purpose of the 20 mL saline flush after the initial dose?

According to official administration protocols, a saline flush is immediately given after the adenosine injection. This rapid follow-up ensures the drug is quickly delivered to the central circulation. Since adenosine has an extremely short duration of action, the flush helps the medication reach the heart effectively and rapidly.

---

Q: How long after the initial 6 mg dose can the second 12 mg dose be administered?

If the intended effect is not achieved by the initial dose, regulatory protocols permit a second dose. Official guidelines indicate that the second dose may be administered within the time limits specified in the protocol, typically 1 to 2 minutes after the first dose.

---

Q: How long does it take for Adenosine to be fully cleared from the body?

Adenosine is a naturally occurring substance and is metabolized, or broken down, extremely quickly in the body. The half-life of the drug in the blood is reported to be less than 10 seconds. This rapid clearance is the reason its physiological effects are so brief.

---

Q: What are the most common side effects a patient should expect to feel?

Regulatory documents list several effects as very common, meaning they are observed frequently during clinical use. These common adverse reactions include brief facial flushing (redness), chest discomfort or pain, a sense of breathlessness (dyspnea), and headache. These temporary effects generally resolve quickly.

---

Q: How is the dosage for a child determined?

For pediatric patients, the acute dosing is weight-based. Official information states the dose is carefully calculated based on the child's body weight and may be escalated by the clinician if necessary, according to specific pediatric guidelines.

---

Q: What is the difference between PSVT and Atrial Fibrillation, and why is Adenosine used for one but not the other?

Adenosine is approved and indicated for use in a specific fast heart rhythm called Paroxysmal Supraventricular Tachycardia (PSVT). The drug is not indicated for Atrial Fibrillation. Official information indicates that use in certain irregular heart rhythms could be harmful, especially if certain pre-excitation pathways are present in the heart.

---

Q: Is it normal to feel like you've been briefly 'shocked' or had your heart stop after getting Adenosine?

The medication causes a profound, but temporary, slowing or blocking of the heart's electrical impulse. The rapid electrical slowing is associated with very common adverse reactions, such as temporary chest discomfort, pressure, or shortness of breath (dyspnea). Though rare, serious adverse reactions documented in regulatory data include fatal cardiac arrest (asystole).

---

Q: What type of procedure is required for the continuous infusion during a stress test?

When used during a pharmacological cardiac stress test, adenosine is administered through a continuous intravenous (IV) infusion. The procedure requires continuous cardiac monitoring, including surveillance of heart rate, blood pressure, and EKG, under strict medical supervision.

---

Q: Why is it so important to avoid throwing away unused medication via household waste?

Pharmaceutical waste guidelines advise against disposing of this medicine via household trash or wastewater systems. This rule ensures adherence to environmental and pharmaceutical waste regulations. Official rules require consulting a pharmacist or following local pharmaceutical guidelines for proper disposal procedures.

Adenosine Injection requires specific environmental controls to maintain stability. The medicine must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Refrigeration is strictly prohibited because the active ingredient may crystallize. If crystallization occurs, the container must be warmed to room temperature to dissolve the crystals, ensuring the solution is clear at the time of use.

Since the injection is a single-use product and contains no preservative, any unused portion of the vial or syringe must be immediately discarded.

For safety, the medication must be kept out of the sight and reach of children.

Disposal must adhere to pharmaceutical waste rules: the medicine should not be thrown away via wastewater or household waste. Consult a pharmacist for proper disposal procedures in accordance with local regulations.